HOW DOCTORS ARE USING THESE POWERFUL CELLS TO STEM HAIR LOSS. FROM THIS FREEZER COME AS SMALL BOX, WITH A BIG PROMISE. GETTING TO THE ROOT OF HAIR LOSS. MAKES SO UPSET. THAT I DON'T LIKE THAT. IT'S SOMETHING THAT I HAVE TOO LEARN HOW TO DEAL WITH THAT. FEMALE PATTERN LIVES IN THE GENES. IT BECAME WORSE AFTER THE BIRTH OF HER FIRST CHILD. TWO PHOTOS. SHE HAS COME TO CARE LOSS SPECIALIST FOR A UNIQUE TREATMENT AND INJECTION COME POE OF HER OWN PLATE LET RICH PLASMA WORKED WITH FREEZE-DRIED STEM CELLS. IT IS HUMAN TISSUE, SO THERE'S NO RISK OR SIDE EFFECTS. APPROVE THE FUNCTIONS OF THE HAIR FOLLICLES THAT CREATE THIN HIS PICTURE HAIR. THE KEY IS TO ACT BEFORE THE FOLLICLES HAVE DIED. A LOT LESS EXPENSIVE THAN A HAIR TRANSPLANT, AND IT CAN WORK AS A STOP. IN SOME AREAS THAT MAY BENEFIT FROM NONINVASIVE TREATMENT BEFORE NEEDING THE HAIR TRANSPLANT. TYPICALLY PATIENTS SEE CHANGES IN THEIR HAIR QUALITY WITHIN FOUR TO EIGHT WEEKS AND MAY HAVE CONTINUES IMPROVE FOR UP TO 18 MONTHS. . IT IS GOING TO MAKE ME HAPPY. THAT'S WHAT I HOPE, THEY FEEL HAPPY WHEN I LOOK IN THE MIRROR. THE PROCEDURE COSTS $2,500. SIMILAR TO OTHER NONINVASIVE COSMETIC TREATMENTS. THE PROCESS WILL TAKE YOU ABOUT AN HOUR, AND IT CAN BE REPEATED IF HAIR GROWTH AND QUALITY BEGIN TO SOMEHOW DROP OFF. WITH YOUR HEALTH NEWS, LOCAL 10 NEWS. KRISTY, TELLS US IT IS IMPORTANT TO NOTE THE TREATMENT

See the original post:
Stem cell therapy helps slow hair lossWhe

May 18, 2014

Image Caption: Stem cells loaded with cancer-killing herpes virus attack a brain tumor cell. Tumor cells in green. oHSV-loaded stem cells in red. oHSV-infected tumor cells in yellow. Credit: Khalid Shah/MGH

Harvard Stem Cell Institute (HSCI)

Harvard Stem Cell Institute (HSCI) scientists at Massachusetts General Hospital have a potential solution for how to more effectively kill tumor cells using cancer-killing viruses. The investigators report that trapping virus-loaded stem cells in a gel and applying them to tumors significantly improved survival in mice with glioblastoma multiforme, the most common brain tumor in human adults and also the most difficult to treat.

The work, led by Khalid Shah, MS, PhD, an HSCI Principal Faculty member, is published in the Journal of the National Cancer Institute. Shah heads the Molecular Neurotherapy and Imaging Laboratory at Massachusetts General Hospital.

Cancer-killing or oncolytic viruses have been used in numerous phase 1 and 2 clinical trials for brain tumors but with limited success. In preclinical studies, oncolytic herpes simplex viruses seemed especially promising, as they naturally infect dividing brain cells. However, the therapy hasnt translated as well for human patients. The problem previous researchers couldnt overcome was how to keep the herpes viruses at the tumor site long enough to work.

Shah and his team turned to mesenchymal stem cells (MSCs)a type of stem cell that gives rise to bone marrow tissuewhich have been very attractive drug delivery vehicles because they trigger a minimal immune response and can be utilized to carry oncolytic viruses. Shah and his team loaded the herpes virus into human MSCs and injected the cells into glioblastoma tumors developed in mice. Using multiple imaging markers, it was possible to watch the virus as it passed from the stem cells to the first layer of brain tumor cells and subsequently into all of the tumor cells.

So, how do you translate this into the clinic? asked Shah, who also is an Associate Professor at Harvard Medical School.

We know that 70-75 percent of glioblastoma patients undergo surgery for tumor debulking, and we have previously shown that MSCs encapsulated in biocompatible gels can be used as therapeutic agents in a mouse model that mimics this debulking, he continued. So, we loaded MSCs with oncolytic herpes virus and encapsulated these cells in biocompatible gels and applied the gels directly onto the adjacent tissue after debulking. We then compared the efficacy of virus-loaded, encapsulated MSCs versus direct injection of the virus into the cavity of the debulked tumors.

Using imaging proteins to watch in real time how the virus combated the cancer, Shahs team noticed that the gel kept the stem cells alive longer, which allowed the virus to replicate and kill any residual cancer cells that were not cut out during the debulking surgery. This translated into a higher survival rate for mice that received the gel-encapsulated stem cells.

Link:
Herpes-Loaded Stem Cells Used To Kill Brain Tumors